|
(V1262) |
Exercise hemodynamic profile of patients with heart failure with preserved versus mid-range ejection fraction |
| |
|
A. Rieth, M. J. Richter, K. Tello, W. Seeger, V. Mitrovic, C. W. Hamm (Bad Nauheim, Gießen) |
|
|
Diskussion |
|
(V1263) |
Skeletal muscle dysfunction in patients with heart failure with preserved ejection fraction occurs independently of age and physical activity and leads to worse exercise capacity and quality of life |
| |
|
T. Bekfani, S. Derlien, A. Hamadanchi, E. Fröb, J. Nisser, U. Smolenski, G. Lehmann, G. Wolf, S. Möbius-Winkler, P. C. Schulze (Jena) |
|
|
Diskussion |
|
(V1264) |
Acute pharmacological stimulation of the soluble guanylate cyclase does not improve left ventricular compliance despite increased myocardial titin phosphorylation in porcine early HFpEF. |
| |
|
M. Schwarzl, A. Alogna, N. Hamdani, M. Manninger, B. Zirngast, B. Kloth, P. Steendijk, W. A. Linke, B. Pieske, S. Blankenberg, D. Westermann, H. Post (Hamburg, Berlin, Bochum, Mülheim an der Ruhr; Graz, AT; Leiden, NL) |
|
|
Diskussion |
|
(V1265) |
Elevated Galectin-3 level at baseline indicate worse long-term outcome in heart failure with preserved ejection fraction (HF-pEF) |
| |
|
K. Hellenkamp, M. Mervai, M. Mende, D. von Grünhagen, M. Weber-Krüger, S. Werhahn, W. Backhoff, G. Hasenfuß, F. Edelmann, R. Wachter (Göttingen, Leipzig, Berlin) |
|
|
Diskussion |
|
(V1266) |
GLP-1 Improves Diastolic Function and Survival in Heart Failure with Preserved Ejection Fraction |
| |
|
T. D. Nguyen, Y. Shingu, P. A. Amorim, M. Schwarzer, T. Doenst (Jena; Sapporo, JP) |
|
|
Diskussion |
|
(V1267) |
Antisense therapy against RBM20 as a potential therapeutical approach for HFpEF patients |
| |
|
C. Maleck, Q. Zhou, B. Neupane, H. Granzier, M. Gawaz, M. Gramlich (Tübingen, Tucson) |
|
|
Diskussion |